Manufacturing Lilly inflates US facility investment spending by $4.5bn PharmaphorumHaving already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.Read full story pharminent May 6, 2026 (Last updated: May 7, 2026) Pharmaphorum Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante. Read full story Post navigation Previous: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand OversightNext: Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026